Member Info for itsyou

It explains the resource well, with the veins being narrow. This bit in particular.

"Mineralization can be narrow and high grade (e.g. 0.25-2.0 m at 5-10 g/t) or more diffuse (e.g. 5-10 m at +/- 2 g/t)."
and
"The presence of additional veins at the foot of the hill, masked by the colluvial rubble, and which would have been missed by (passing South of) the adits and surface drillholes is a possibility that should be investigated."

The full CPR is worth a read, well the whole prospectus is too, as I've done.

The DD drilling may show up similar results, although they've mentioned that they hope it may get wider deeper down. It should be easy to quickly prove up more Measured Oz.

It's the RC drilling that is of more interest to me. The economics of high grade open pit, against current underground thin vein mining would be pretty impressive, considering the profit they are making now!

AG, 5 Holes are on Page 29 of the CPR, or Page 180 of the RTO prospectus

https://caracalgold.com/wp-content/uploads/2021/07/Prospectus-Final-19.07.21.pdf

You posted 3 days ago!

JV? Don't think so.

https://tinyurl.com/yc45y5h7

From 16:45

https://www.**********.co.uk/articles/alan-green-talks-about-ab-dynamics-moonpig-and-caracal-gold-c2b55c9/

"Not all aim companies keep their investors so well informed" - Caracal aren't on AIM, they're on the main LSE market :-)

For full note : https://vsacapital.com/investment-market-research-portal/#/portal/vsa-capital/research/23734fde-9ee6-4666-a30c-0de6bdf771fe

Page 23 in the Valuation section

"We believe that 1mnoz plus can be achieved at Kilimapesa and that implies 5.6p/sh. Our base case continues to demonstrate strong upside potential, however. Given a significant uplift in resource size is expected in the near term, there is a clear pathway to increasing our valuation target."

This may have been holding some investors back from investing, as the renewal was pending as per RTO prospectus :

"KGPL’s renewal of PL/2018/0189 is currently in process and pending approval by the Mining License Review
Board (“MRB”). As of the date of this Document, the MRB’s approval remains outstanding. The Directors are
confident that the exploration license will be approved in 2021. Renewal of the PL/2018/0189 exploration license
is not material to KPGL’s ongoing mining operations. "

https://caracalgold.com/wp-content/uploads/2021/07/Prospectus-Final-19.07.21.pdf

Also, finance can be raised off the back of the acquisition itself, especially one with reserves and a FS.

They've already quoted publicly that they intend to use both sides of the balance sheet, obtaining finance on the back of Killi(12k oz pa @ $900 margin = $10.8m pa profit)

Look at the CV of JB, who funded mines in Tanzania for Resolute Mining
Look at the experience of financing in the rest of the BOD
Look at the experienced mine builders, who've now proven themselves at Killi

Then look at what someone else intended to pay for the Tanz lands under consideration ;-)

Suggins

The first 3M in 36-48m is for Killi

The second 3M in 12-18m is for GCAT - "across our East African-focused gold mining and exploration activities" helped by the pending acquisition that has Reserves as well as Resources :-) DYOR

"With gold going up in $ and the £ coming down things look even better." - It's the only one I look at seeing, seeing as a UK investor my stock is valued in GBP.

Broke £1350 and some blue sky; see my screen grab : https://ibb.co/jz38xQQ

Corrected ;-) "They had $450000" as per Sep numbers.

As Robbie said 2 days ago, production has increased 25% from Sep to Oct and they expect another 25% increase from Oct to Nov.

A lot of that volume will be down to Traders, in and out, especially as GCAT hit the top riser of the day list, then taking their losses.

Frankfurt has only traded 343,999 shares since IPO and as Jason has said, most of the German volume has gone through LSE.

The Brokers took shares in shares as payment for the RTO(look at the prospectus!) and I can't see anywhere where they were tied in

try this
https://bit.ly/3q4Tf3I

There's also a longer video interview just out on **********

https://www.**********.co.uk/articles/oncimmune-discuss-their-highly-profitable-immunoinsights-business-b95d977/

"This equals (AISC $965 + $700(plant upgrades))" - No, the $985(not 965) figure is cash costs. The AISC number will be between that and the total cost of1694. Where that is in the range depends on how much sustaining capital they spent. As I mentioned before; why they even added exploration costs to get to that 1,694 number, I don't know.

But anyway, these are all rea view numbers from September, prior to all the recent upgrades which also had a knock on affect on the Sept numbers, due to the plant being down for those upgrades.

Watch for yourself - https://www.youtube.com/watch?v=GqyNNcz-S4Y&t=10s

"In my experience a new broker" - They are not new. In fact they've reduced the number of Brokers to 2. Does that mean they are planning a share buy back? ;-)

Being serious now; that decision maybe aligned with their cost reduction initiative they've had in place for a few years.

Was :
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Singer Capital Markets (Joint Broker)
WG Partners (Joint Broker)

Now :
Singer Capital Markets (Nominated Adviser and Joint Broker)
WG Partners (Joint Broker)